European cardiovascular and kidney health guidelines

European medical experts have released updated clinical guidelines emphasizing the interconnectedness of cardiovascular disease, chronic kidney disease (CKD), and body weight.

Initial guidance focused on the necessity of integrated treatment paths to prevent the exacerbation of these conditions. Experts recommended routine kidney function monitoring, including annual blood and urine tests, for all individuals with cardiovascular disease to ensure early detection of asymptomatic CKD.

Subsequent updates from the European Society of Cardiology (ESC) and the European Renal Association (ERA) expanded this scope to include obesity as a central link. The guidelines now highlight the role of GLP-1 medications, such as semaglutide, alongside finerenone for managing cardiovascular risk and slowing kidney damage in patients with type 2 diabetes and CKD. Additionally, the guidelines note the high risk of arrhythmias and sudden cardiac death in patients undergoing hemodialysis, while acknowledging a lack of specific data regarding the safety of certain antiarrhythmic drugs and ablation therapies for this population.